Or­p­hazyme agrees to sell it­self, and its 'pipeline-in-a-prod­uct,' to Kem­Pharm

Two months ago, Or­p­hazyme en­list­ed the help of the Dan­ish courts to help over­see a re­struc­tur­ing in the wake of tri­al fail­ures, C-suite shake­ups and reg­u­la­to­ry re­jec­tions. The move was ex­pect­ed to help the com­pa­ny find a way to ei­ther sell it­self or its as­sets, at­tempt­ing to keep the re­search go­ing on what it once called its “pipeline-in-a-prod­uct.”

On Sun­day, the res­o­lu­tion of the court-run ef­forts came in­to view.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER